Mahamaya Lifesciences IPO is set to open for subscription on November 11, 2025, and will close on November 13, 2025. This is a Book Built Issue IPO, aiming to raise around ₹70.44 crores, which includes a fresh issue of ₹64.28 crores and an offer for sale of up to 5,40,800 equity shares with a face value of ₹10 each. The IPO price band has been fixed at ₹108 to ₹114 per share, offering investors a fair entry point based on the company’s growth prospects.
The Mahamaya Lifesciences IPO allotment date is scheduled for November 14, 2025, and the shares are expected to be listed on BSE on November 18, 2025. The retail investor quota stands at 35%, while QIBs hold 50% and HNIs get 15% of the allocation. This balanced structure indicates a healthy mix of investor participation, providing opportunities for both institutional and retail investors.
Financially, Mahamaya Lifesciences has shown strong growth, with revenue rising to ₹267.17 crores in 2025 compared to ₹162.83 crores in 2024. The net profit also surged to ₹12.94 crores in 2025, up from ₹5.22 crores in 2024, reflecting solid business expansion and profitability. Considering its consistent performance and improving margins, long-term investors may find this IPO a promising opportunity for steady returns.
Table of contents
- Mahamaya Lifesciences IPO Date & Price Band Details
- Mahamaya Lifesciences IPO Market Lot
- Mahamaya Lifesciences IPO Reservation
- Mahamaya Lifesciences IPO Anchor Investors
- Mahamaya Lifesciences IPO Allotment & Listing Dates
- Mahamaya Lifesciences IPO: Promoters and Holding Pattern
- Objects of the Issue & Utilisation of proceeds – Mahamaya Lifesciences IPO
- Mahamaya Lifesciences IPO Company Financial Report
- Mahamaya Lifesciences IPO Valuation – FY2025
- Mahamaya Lifesciences IPO Peer Group Comparison
- Mahamaya Lifesciences Company Overview, Key Points, Strengths, and Risks
- IPO Lead Managers aka Merchant Bankers
- Mahamaya Lifesciences IPO Registrar
- Mahamaya Lifesciences Company Address
- FAQs about Mahamaya Lifesciences IPO
Mahamaya Lifesciences IPO Date & Price Band Details
Mahamaya Lifesciences IPO will open on November 11, 2025, and close on November 13, 2025. It’s a Book Built Issue with a price band of ₹108 to ₹114 per share. The IPO aims to raise ₹70.44 crores, including a fresh issue of ₹64.28 crores, and will list on BSE SME.
| IPO Details | Details |
|---|---|
| IPO Open Date | November 11, 2025 |
| IPO Close Date | November 13, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹108 to ₹114 Per Share |
| Issue Size | Approx ₹70.44 Crores |
| Fresh Issue | Approx ₹64.28 Crores |
| Offer for Sale: | Approx 5,40,000 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus | Click Here |
| RHP Draft Prospectus | Click Here |
Mahamaya Lifesciences IPO Market Lot
The Mahamaya Lifesciences IPO lot size is 2 lots (2,400 shares) for retail investors, requiring a minimum investment of ₹2,73,600. For S-HNI, the minimum is 3 lots (3,600 shares) worth ₹4,10,400, while B-HNI investors can apply with 8 lots (9,600 shares) totaling ₹10,94,400.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 2,400 | ₹2,73,600 |
| Retail Maximum | 2 | 2,400 | ₹2,73,600 |
| S-HNI Minimum | 3 | 3,600 | ₹4,10,400 |
| S-HNI Maximum | 7 | 8,400 | ₹9,57,600 |
| B-HNI Minimum | 8 | 9,600 | ₹10,94,400 |
The Mahamaya Lifesciences IPO Subscription Status will be updated after the bidding process begins on Nov 11, 2025.
Mahamaya Lifesciences IPO Reservation
In the Mahamaya Lifesciences IPO, the QIB quota is set at 50%, while NII investors have 15% of the issue reserved. The retail investor portion accounts for 35% of the total shares, ensuring balanced participation across investor categories for a well-diversified IPO subscription structure.
| Investor Category | Share Offered | -% Shares |
|---|---|---|
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Mahamaya Lifesciences IPO Anchor Investors
The Mahamaya Lifesciences IPO anchor bidding date is November 10, 2025. The anchor investor list will be available soon. The anchor portion includes shares worth [.] crores. The lock-in period ends on December 14, 2025 for 50% shares and on February 12, 2026 for the remaining 50%.
| Anchor Event | Date |
|---|---|
| Anchor Bidding Date | November 10, 2025 |
| Anchor Investors List | Click Here |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | December 14, 2025 |
| lock-in period end date 50% shares (90 Days) | February 12, 2026 |
Mahamaya Lifesciences IPO Allotment & Listing Dates
The Mahamaya Lifesciences IPO will open on November 11, 2025, and close on November 13, 2025, with a bidding cut-off time of 5 PM. The basis of allotment is on November 14, refunds and credit to Demat accounts on November 17, and the IPO listing date is November 18, 2025.
| Event | Date |
|---|---|
| IPO Open Date: | November 11, 2025 |
| IPO Close Date: | November 13, 2025 |
| Basis of Allotment: | November 14, 2025 |
| Refunds: | November 17, 2025 |
| Credit to Demat Account: | November 17, 2025 |
| IPO Listing Date: | November 18, 2025 |
| IPO Bidding Cut-off Time: | November 13, 2025 – 5 PM |
Mahamaya Lifesciences IPO: Promoters and Holding Pattern
The promoters of Mahamaya Lifesciences are Mr. Krishnamurthy Ganesan, Mr. Prashant Krishnamurthy, and Mrs. Lalitha Krishnamurthy. The company’s promoter holding pre-issue stands at 77.27% (1,77,66,200 shares), which will reduce to 56.35% (2,34,05,000 shares) post-issue, reflecting equity dilution after the Mahamaya Lifesciences IPO.
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 1,77,66,200 | 77.27% |
| Promoter Holding Post Issue | 2,34,05,000 | 56.35% |
Objects of the Issue & Utilisation of proceeds – Mahamaya Lifesciences IPO
The Mahamaya Lifesciences IPO proceeds will be utilized for key objectives including equipment purchase for the existing formulation plant (₹3.75 crores), setting up a new technical manufacturing plant (₹29.42 crores), construction of a warehouse (₹2.53 crores), working capital requirements (₹18 crores), and general corporate purposes.
| Purpose | Crores |
|---|---|
| Purchase of Equipment for existing Formulation plant. | ₹3.75 |
| Funding capital expenditure towards setting up of a new Technical manufacturing plant. | ₹29.42 |
| Construction of Warehouse Building and Purchase of Machinery. | ₹2.53 |
| Funding working capital requirement of the Company. | ₹18.00 |
| General Corporate purposes. | ₹- |
Mahamaya Lifesciences IPO Company Financial Report
Mahamaya Lifesciences has shown consistent financial growth, with revenue rising from ₹90.16 crores in 2022 to ₹267.17 crores in 2025. The PAT increased from ₹2.72 crores to ₹12.94 crores in the same period, reflecting strong profitability. The total assets also grew significantly to ₹218.87 crores (June 2025).
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2022 | ₹90.16 | ₹86.43 | ₹2.72 | ₹55.71 |
| 2023 | ₹137.40 | ₹132.30 | ₹3.75 | ₹77.88 |
| 2024 | ₹162.83 | ₹155.71 | ₹5.22 | ₹112.07 |
| 2025 | ₹267.17 | ₹249.81 | ₹12.94 | ₹188.35 |
| June 2025 | ₹84.04 | ₹78.35 | ₹4.10 | ₹218.87 |
Mahamaya Lifesciences IPO Valuation – FY2025
The Mahamaya Lifesciences IPO reflects strong financial metrics with an impressive ROE of 34.94% and ROCE of 23.15%. The company reports an EBITDA margin of 9.22%, PAT margin of 4.84%, and EPS of ₹7.60. Its debt-to-equity ratio stands at 1.08, and RoNW is 26.19% with NAV ₹27.82.
| KPI | Values |
|---|---|
| ROE: | 34.94% |
| ROCE: | 23.15% |
| EBITDA Margin: | 9.22% |
| PAT Margin: | 4.84% |
| Debt to equity ratio: | 1.08 |
| Earning Per Share (EPS): | ₹7.60 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 26.19% |
| Net Asset Value (NAV): | ₹27.82 |
Mahamaya Lifesciences IPO Peer Group Comparison
In the peer comparison, Nova Agritech Limited shows an EPS of 3.05, P/E ratio of 16.93, and RoNW of 12.47% with an income of ₹296.60 crores. Bhagiradha Chemicals & Industries Limited reports an EPS of 1.14, P/E ratio of 247.63, and RoNW of 2.03% with ₹449.75 crores income.
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Nova Agritech Limited | 3.05 | 16.93 | 12.47% | 23.76 | 296.60 Cr. |
| Bhagiradha Chemicals & Industries Limited | 1.14 | 247.63 | 2.03% | 52.61 | 449.75 Cr. |
Mahamaya Lifesciences Company Overview, Key Points, Strengths, and Risks
Mahamaya Lifesciences Limited is an integrated agrochemical company primarily engaged in the manufacturing, formulation, and marketing of crop protection and biological solutions. It caters to both domestic (India) and international markets, operating a manufacturing facility in Dahej, Gujarat.
The company was founded in 2002 and initially focused on the import and registration of vital pesticide molecules before evolving into a manufacturer of formulations. It recently launched an Initial Public Offering (IPO) on the BSE SME Platform.
Key Points and Business Segments
- Core Business: Manufacturing and marketing of a diversified product portfolio, including insecticides, herbicides, fungicides, bio-stimulants, biopesticides, and biofertilizers.
- Business Segments: The company operates through four main segments:
- Bulk Formulations Sales (supplying Indian agrochemical companies and MNCs).
- Technical Sales (selling active ingredients).
- Brand Sales (own branded products in the domestic market).
- Export Formulations (exporting to countries like the Dominican Republic, Egypt, Turkey, Jordan, Ethiopia, and the UAE).
- Manufacturing & R&D: Operates a state-of-the-art formulation plant and in-house R&D/Quality Assurance laboratories in Dahej, Gujarat.
- Recent Financial Performance (FY2025): The company has shown significant growth, with revenue up by 64% and Profit After Tax (PAT) up by 148% compared to the previous year (FY2024). Total Income for FY2025 was $\text{₹267.17}$ crore, and PAT was $\text{₹12.94}$ crore.
Strengths of Mahamaya Lifesciences
- Diversified Product Portfolio: Offers a broad range of products (278 registered products as of mid-2025), including a growing focus on sustainable and eco-friendly bio-products (bio-stimulants, biopesticides, biofertilizers), aligning with global trends.
- Registration-Led Strategy: Leveraging promoter experience to identify and register vital molecules ahead of competitors, providing an early-mover market advantage of typically 4-5 years in India.
- Global Export Footprint: Established presence in multiple international markets, with investment in generating registration data applicable across various countries, mitigating reliance solely on the domestic Indian market.
- Integrated Operations & Capacity Expansion: Transitioning from a trader/formulator to an integrated player. The IPO proceeds are earmarked for setting up a new technical manufacturing plant for backward integration, which is expected to reduce dependence on imported raw materials and improve cost control.
- Strong Financial Growth: Demonstrated rapid growth in both top line and bottom line (revenue and PAT) in the most recent fiscal year (FY2025).
Key Risks and Concerns
- Customer Concentration Risk: A significant portion of the company’s revenue is dependent on a few clients. Sales to the top ten customers have consistently accounted for over 70% of total sales, posing a risk if any of these relationships change.
- Dependence on Imports and Forex Volatility: The company has a heavy reliance on imported raw materials (over 58% of sales in FY2025), exposing it to risks related to foreign exchange rate fluctuations, global supply chain disruptions, and increased import costs.
- Agricultural and Climatic Dependency: As an agrochemical company, its performance is closely tied to monsoon conditions and agricultural cycles in India. Unfavorable weather can reduce crop cultivation and demand for its products.
- Sustainability of Recent Growth: The sharp increase in revenue and PAT observed in FY2025 raises questions about its long-term sustainability and competitive position relative to established, larger industry players.
- Cash Flow: The company reported negative cash flow from operating activities in FY2024, which could limit its ability to fund operations, repay debt, and make new investments if it persists.
IPO Lead Managers aka Merchant Bankers
- Oneview Corporate Advisors Pvt.Ltd.
Mahamaya Lifesciences IPO Registrar
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: mahamaya.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
Mahamaya Lifesciences Company Address
Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
FAQs about Mahamaya Lifesciences IPO
The IPO opens for subscription on November 11, 2025, and closes on November 13, 2025.
The IPO Price Band is fixed at ₹108 to ₹114 per equity share.
The minimum lot size for retail investors is 2 lots, which comprises 2,400 shares, requiring a minimum investment of ₹2,73,600 (at the upper price band).
The total Mahamaya Lifesciences IPO issue size is approximately ₹70.44 Crores.
The shares are tentatively scheduled to be listed on the BSE SME platform on November 18, 2025.
The proceeds from the fresh issue will primarily be used for setting up a new technical manufacturing plant, funding working capital requirements, purchasing equipment for the existing plant, and general corporate purposes.
The company has shown strong growth, with revenue rising from ₹162.83 Crores in FY2024 to ₹267.17 Crores in FY2025, and Net Profit (PAT) surging from ₹5.22 Crores to ₹12.94 Crores in the same period.
The Retail Individual Investor (RII) quota stands at 35% of the Net Offer.
The Mahamaya Lifesciences IPO will be listed on the BSE SME platform.
The promoters are Mr. Krishnamurthy Ganesan, Mr. Prashant Krishnamurthy, and Mrs. Lalitha Krishnamurthy.
Disclaimer: This content is provided strictly for educational and informational purposes only. The securities or investments mentioned are based on publicly available information and should not be construed as investment advice or recommendations. Investors are advised to consult with their financial advisor before making any investment decisions.
